Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Nemolizumab in Adolescents with Moderate-to-Severe Atopic Dermatitis
NCT03921411Phase 2Completed
- Sponsor
- Galderma
- Start
- Apr 2019
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Primary endpoints: Nemolizumab Serum Concentrations at 24 weeks, Apparent Clearance After Extravascular Administration at 24 weeks and 10 more. Started Apr 2019; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03921411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921411.